Company: GNMSF
Filing Date: 2025-08-07
Form Type: 6-K
Source: 0001434265-25-000063
Chunk: 51

Company: GENMAB A/S
Filing Date: 2025-08-07
Form: 6-K
Chunk 51
---
 lease liabilities   |     | $ |           148 |     | $ |               144 |

During the first six months of 2025, there were no material additions to Genmab’s right-of-use assets and lease liabilities. During the first six months of 2024, there were additions to Genmab’s right-of-use assets and lease liabilities related to the commencement of leases in the U.S. with respect to office and laboratory space and in Japan with respect to office space.

| Genmab A/S            
 Carl Jacobsens Vej 30 
 2500 Valby, Denmark   |     | Tel: +45 7020 2728 
 www.genmab.com     |     | Company Announcement no. 40 
 Page 41/44                  
 CVR no. 2102 3884           |

#### Interim Report for the First Half of 2025
Amounts recognized in the Condensed Consolidated Statements of Comprehensive Income

The Condensed Consolidated Statements of Comprehensive Income show the following amounts relating to leases:

| Depreciation charge of right-of-use assets       |     | Three Months Ended June 30, 
 2025                        |   |     | 2024 |   |     | Six Months Ended June 30, 
 2025                      |   |     | 2024 |   |
|:-------------------------------------------------|:----|:----------------------------|--:|:----|:-----|--:|:----|:--------------------------|--:|:----|:-----|--:|
| Properties                                       |     | $                           | 4 |     | $    | 4 |     | $                         | 8 |     | $    | 7 |
| Total depreciation charge of right-of-use assets |     | $                           | 4 |     | $    | 4 |     | $                         | 8 |     | $    | 7 |

Variable lease payments, short-term lease expense, lease interest expense and low-value leases are not material.

Note 10 - Contingencies

Chugai Patent Infringement Complaint

In 2024, Chugai filed a lawsuit in the Tokyo District Court, Japan against AbbVie’s and Genmab’s subsidiaries in Japan asserting that their activities with EPKINLY (epcoritamab) in Japan infringe twoJapanese patents held by Chugai, JP6278598 and JP6773929. Chugai is claiming damages and injunctive relief